What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2024-11-04 compared with 2024-08-01 · 33 added, 34 removed, 30 unchanged (69% of the section changed)

6 unchanged sentences

During the quarterly period covered by this report, none of our directors or officers entered into or terminated a Rule 10b5-1 trading arrangement or adopted or terminated a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) except as follows:

On June 10, 2024 , for estate and financial planning purposes, Marianne De Backer , M.Sc., Ph.D., MBA, our Chief Executive Officer , adopted a Rule 10b5-1 trading plan for the sale of our common stock that is intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) (the “De Backer Trading Plan”).

The De Backer Trading Plan provides for a sale of 18,000 shares in a limit order, which order will be in effect from approximately September 11, 2024 to December 31, 2024 .

The sales are intended to generate funds to satisfy Dr.

De Backer’s tax obligation in connection with the vesting in April 2024 of shares pursuant to a restricted stock unit (“RSU”) award.

On July 15, 2024, the Company issued restricted stock units (“RSUs”) subject to mandatory sell-to-cover tax withholding arrangements intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) to Mark Eisner, M.D., M.P.H., our Executive Vice President and Chief Medical Officer.

On August 5, 2024 , for estate and financial planning purposes, Dr.

Eisner , adopted a Rule 10b5-1 trading plan for the sale of our common stock that is intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) (the “Eisner Trading Plan”).

The Eisner Trading Plan provides for a sale of up to 53,125 shares issuable upon the exercies of stock options pursuant to limit orders, which orders will be in effect from approximately July 15, 2025 to December 31, 2025 .

The Eisner Trading Plan also provides for a sale of RSU shares pursuant to a market order and a limit order, which orders will be in effect from approximately July 17, 2025 to December 31, 2025.

The RSU share sales are intended to generate funds to satisfy Dr.

Eisner’s tax obligation in connection with the RSU shares that will vest in 2025 pursuant to the RSU award granted to him on July 15, 2024.

The number of RSU shares that will be sold under this arrangement is not currently determinable as the number will vary based on the extent to which vesting conditions are satisfied, the Company’s stock price and the number of RSU shares that are sold upon vesting pursuant to the mandatory sell to cover tax withholding arrangements described above.

Under the Company’s 10b5-1 plan guidelines, Dr.

De Backer is prohibited from selling more than 50,000 shares in a single trading day.

The De Backer Trading Plan will expire upon the earlier of (i) the date all sales contemplated by the De Backer Trading Plan have been executed, or (ii) December 31, 2024.

On June 10, 2024 , for estate and financial planning purposes, Janet Napolitano , a member of our Board of Directors , adopted a Rule 10b5-1 trading plan for the sale of our common stock that is intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) (the “Napolitano Trading Plan”).

The Napolitano Trading Plan provides for potential trading activity from approximately September 11, 2024 to August 31, 2025 , and includes both market and limit orders covering up to an aggregate of 23,806 shares of our common stock to be sold.

Under the Company’s 10b5-1 plan guidelines, Ms.

Napolitano is prohibited from selling more than 50,000 shares in a single trading day.

The Napolitano Trading plan will expire upon the earlier of (i) the date all sales contemplated by the Napolitano Trading Plan have been executed, or (ii) August 31, 2025.

On June 15, 2024, the Company issued RSUs subject to mandatory sell-to-cover tax withholding arrangements to Ruju Bhatt Srivastava, M.D., the Company’s Executive Vice President, Program Leadership and Management.

Additionally, on April 22, 2024 , and May 21, 2024 , (each, an applicable “Adoption Date”), respectively, Dr.

Srivastava and Mark Eisner , M.D., M.P.H., the Company’s Executive Vice President and Chief Medical Officer , each entered into a 10b5-1 trading arrangement that is intended to qualify as an “eligible sell-to-cover transaction” (as described in Rule 10b5-1(c)(1)(ii)(D)(3) of the Exchange Act) with respect to certain RSUs (the “Sell-to-Cover Instructions”).

The Sell-to-Cover-Instructions provide for the automatic sale of shares of our common stock that would otherwise be issuable on each settlement of RSUs in amounts necessary to satisfy the Company’s applicable tax withholding obligation, which is based on the fair market value of the shares of the Company’s common stock subject to the RSUs that are settled on each applicable vesting date.

The proceeds of any such sale will be delivered to the Company in satisfaction of such tax withholding obligations.

The Sell-to-Cover Instructions are subject to applicable “cooling-off periods”, consistent with Rule 10b5-1(c)(1)(ii)(B) of the Exchange Act.

Srivastava’s and Eisner’s Sell-to-Cover Instructions apply with respect to the first award of RSUs granted on or after their respective hire dates and any RSUs that may, from time to time following such date, be granted to them by the Company, other than any future granted RSUs which by the terms of the applicable award agreements require the Company to withhold shares to satisfy tax withholding obligations in connection with the vesting and settlement of such RSUs, and therefore do not permit sell-to-cover transactions.

The number of shares that will be sold under these RSU sell-to-cover tax withholding arrangements is not currently determinable as the number will vary based on the extent to which vesting conditions are satisfied and the market price of our common stock at the time of settlement.

Appointment of Certain Officers

On July 30, 2024, our Board of Directors appointed Dr.

De Backer as principal financial officer and principal accounting officer of the Company.

De Backer’s biographical information is disclosed in the Company’s Current Report on Form 8-K filed with the U.S.

Securities and Exchange Commission (the “Commission”) on January 25, 2023, and in the Company’s definitive proxy statement filed with the Commission on April 19, 2024, and such biographical information is incorporated herein by reference.

There are no arrangements or understandings between Dr.

De Backer and any other persons pursuant to which she was selected as the Company’s principal financial officer and principal accounting officer.

There are no family relationships between Dr.

De Backer and any director or executive officer of the Company.

De Backer has no direct or indirect interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K .

De Backer will not receive any adjustment to her compensation or any additional compensation in connection with performing the functions of principal financial officer and principal accounting officer of the Company.

Eisner is prohibited from selling more than 50,000 shares in a single trading day.

The Eisner Trading Plan will expire upon the earlier of (i) the date all sales contemplated by the Eisner Trading Plan have been executed, or (ii) December 31, 2025 .

(a) Exhibits.

4 unchanged sentences

001-39083), filed with the SEC on March 8, 2023).

31.1 Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

License Agreement between the Company and Amunix Pharmaceuticals, Inc.

, dated as July 31, 2024

Offer Letter between the Company and Jason O'Byrne, dated September 6, 2024

Amendment No.

2 to the Other Transaction for Advanced Research (OTAR) between the Company and the United States of America Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority, concerning Pre-exposure Prophylactic Monoclonal Antibodies for the Prevention of Influenza Illness and Medical Countermeasures for Other Emerging Pathogens of Pandemic Potential (Agreement No.

75A50122C00081, Amendment No.

P0000 2 ), dated January 18 , 2024

A mendment No.

3 to the Other Transaction for Advanced Research (OTAR) between the Company and the United States of America Department of Health and Human Services, Administration for Strat e gic Preparedness and Response, Bi omedical Advanced Rese arch and Development Authority, concerning Pre-exposure Prophylactic Monoc lonal An tibodies for the Prevention of Influenza and Medical Countermeasures for Other Emerging Path ogens of Pandemic Potential (Agreement No.

75A0122C00081, Amendment No.

P00003), dated September 9, 20 24

31.1 Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2 Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1* Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C.

8 unchanged sentences

____________________________________________________________________

+ Indicates a management contract or compensatory plan or arrangement.

† Certain portions of this exhibit (indicated by “[***]”) have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.

* The certification attached as Exhibit 32.1 accompanies this Quarterly Report on Form 10-Q pursuant to 18 U.S.C.

Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VIR BIOTECHNOLOGY, INC.

August 1, 2024

November 4, 2024

/s/ Marianne De Backer

1 unchanged sentence

Chief Executive Officer and Director

(Principal Executive Officer and Principal Financial Officer)

(Principal Executive Officer)

November 4, 2024

/s/ Jason O'Byrne

Jason O'Byrne

Executive Vice President and Chief Financial Officer

(Principal Financial Officer)

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information